# Hetero Drugs

Source: https://onco.cc/companies/hetero/  
OnCo record `hetero` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A privately held Hyderabad generics group, the world's largest maker of HIV antiretrovirals, which launched Indian biosimilars of rituximab in 2015 and bevacizumab in 2016.

## Summary

Hetero Drugs was founded in 1993 by B. Parthasaradhi Reddy, formerly chief technologist at Dr. Reddy's, and operates in more than 145 countries with over 30,000 employees. Best known as the largest producer of antiretroviral drugs and for low-cost hepatitis C generics, it has built a biosimilars portfolio for India that includes rituximab (2015, for non-Hodgkin lymphoma and chronic lymphocytic leukaemia), darbepoetin alfa (2015) and bevacizumab (2016, for metastatic colorectal cancer), and it supplies oncology active ingredients and generics globally.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Hyderabad
- Type: pharma
- Website: https://hetero.com

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Hetero_Drugs
- Official website: https://web.archive.org/web/20220505192107/https://www.heteroworld.com/

## Connected records

- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [CD20](https://onco.cc/targets/cd20/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Rituximab](https://onco.cc/drugs/rituximab/)
- terms: [Biosimilar](https://onco.cc/terms/biosimilar/)
- bottlenecks: [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)

---
JSON: https://onco.cc/api/v1/entities/hetero.json